Prescient Therapeutics targets $7 million raise to advance PTX-100 cancer program

Prescient Therapeutics Ltd (ASX:PTX) is seeking to raise up to $7 million through a Share Purchase Plan (SPP) to advance its first-in-class cancer treatment, PTX-100, through a key clinical development milestone and into its next stage.